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Abstract: Type II DNA topoisomerases (EC 5.99.1.3) are enzymes that catalyse topological changes in
DNA in an ATP dependent manner. Strand passage reactions involve passing one double stranded
DNA duplex (transported helix) through a transient enzyme-bridged break in another (gated helix).
This activity is required for a range of cellular processes including transcription. Vertebrates have two
isoforms: topoisomerase IIα and β. Topoisomerase IIβwas first reported in 1987. Here we review the
research on DNA topoisomerase IIβ over the 30 years since its discovery.
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1. Discovery of DNA Topoisomerase IIβ (TOP2B) Protein
In 1987 the first report of a second type II isoform in mammalians was published by Fred Drake’s
group at Smith Kline French (SKF); this isoform was called DNA topoisomerase IIβ (TOP2B) [1].
The purification of topoisomerase IIβwas from a murine P388 leukemia cell line selected for resistance
to amsacrine [2]. This amsacrine resistant cell line also displayed resistance to other drugs that targeted
topoisomerase II, but not to camptothecin which targets topoisomerase I. When topoisomerase II was
purified from the resistant cell line and the sensitive cell line, two different sized bands were seen
on SDS-PAGE gels, one of 170 KDa (p170) and the other 180 KDa (p180), but the relative amounts
were different in the sensitive and resistant cell lines. Partial proteolysis with Staphylococcus V8
protease revealed different cleavage products with p170 and p180, suggesting that they were different
isoforms. Antibodies were raised to each of the two purified proteins and used on western blots of cell
lysates prepared by boiling immediately in SDS. The antibodies recognised specifically p170 or p180,
supporting the distinct identities of the two proteins and discounting the alternative explanation that
the p170 was a proteolytic fragment of the p180 (one suggestion in the field at that time).
Interestingly, two other studies published at this time also provided evidence for a second type II
isoform. Joseph Holden and his team were analysing levels of topoisomerase activity and found TOP2
activity in non-proliferating tissue, which was contrary to the previous idea that only proliferating
cells contain type II topoisomerase activity; they suggested this was evidence that human tissues may
contain more than one form of the enzyme [3]. Joaquim Roca and Cristobal Mezquita were analysing
the role of topoisomerases in chromatin changes during spermatogenesis. The presence of type II DNA
topoisomerase activity in both replicating chicken testis cells and in non-replicating chicken spermatids
provided evidence that there may be a second isoform of topoisomerase II in non-replicating cells [4].
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2. Cloning the cDNA Encoding TOP2B
Before whole genome sequencing, obtaining coding sequences was a very time consuming process.
Three groups working independently reported the cloning of partial cDNAs encoding TOP2B, using
various approaches. Fred Drake and K.B. Tan’s team used a Drosophila Top2 to screen a cDNA library
derived from human Raji-HN2 cells; they cloned two classes of cDNAs reported in Chung et al. [5].
One class was identical in sequence to part of the cDNA cloned for TOP2 by Monica Tsai-Pflugfelder
et al. in 1988 [6]. The second class of cDNA shared 75% nucleotide identity with the other class.
These were partial clones (SP1 and SP11) for the two different isoforms: topoisomerase IIα (TOP2A)
and topoisomerase IIβ (TOP2B); the region encoded by clone SP11 is shown in Figure 1.
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The ATPase domain is shown in red, the breakage-reunion domai in green and the C-terminal domain
in blue. The positions of conserved motifs are . The line underneath shows the location
of site-direct d mutations reported by West et al. [7] (above) and mutations selected for drug resistance
reported in L ontiou et al. [8] (below). The locations of inter-domain hinge reg ons elucidated by
limited proteol sis reported in Austin et al. [9] are also shown. At the bottom of Figure 1, the locations
of the initial partial cDNA clones encoding portions of TOP2B are sh wn [5]; SP11, and CAA5, clone
CAA6, confirming that CAA5 and SP11 were part of the same gene, are also shown [10,11].
In a parallel study, a novel topoisomerase II cDNA clone was identified adjacent to the region
cloned by Chung et al. [10]. Two types of clone were identified, CAA4 a d CAA5; CAA4 was identical
to part of the TOP2A identified by Tsai-Pflugfelder et al., in 1988 from HeLa [6] cells and CAA5 was
a novel cDNA, which shared 62% identity with TOP2A and aligned with the end of the SP11 clone
reported by Chung et al. [5]. The region encoded by clone CAA5 is shown in Figure 1. These clones were
isolated from a human HeLa cell lambda GT10 cDNA library by screening with a small, 231 bp cDNA
(CAA1) that had been isolated by expression screening using a polyclonal antisera raised to calf thymus
topoisomerase II [12]. Further screening isolated larger clones (CAA6 and CAA7) that confirmed this
novel cDNA was part of TOP2B. Clustal alignments of the sequences determined that TOP2A and
TOP2B shared homology with topoisomerases from other species and that there were motifs conserved
across all species. These conserved motifs are shown in Figure 1 [9,11]. Tsutsui et al., 1993 [13] isolated
TOP2B cDNA clones from rat by reverse transcriptase PCR using degenerate oligonucleotides encoding
regions conserved between human and Drosophila topoisomerase II. The full coding sequence for
TOP2B was also reported by Jenkins et al., 1992 [14], using a size selected cDNA library screened by
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hybridisation using a PCR product generated with primers whose sequences were derived from the
previously published partial clones. The chromosomal mapping revealed human topoisomerase IIα
(TOP2A) is located on chromosome 17 [6,15] and human topoisomerase IIβ (TOP2B) on chromosome
3 [14,15]. These studies confirmed that TOP2B is a new isoform, not a splice variant, of TOP2A.
The TOP2B gene was subsequently cloned and confirmed TOP2B was a paralog of TOP2A having
arisen by gene duplication of TOP2A [16,17]. A splice variant of TOP2B was reported by Davies et al.,
in 1993 [18]. There have been several studies on TOP2B gene regulation; the TOP2B promoter lacks a
canonical TATA box [19,20]. Promoter activity is regulated by nuclear factor-Y (NF-Y)- and specificity
protein-1 (Sp1) [20]. TOP2B expression has also been reported to be regulated by Nurr1 [21]. TOP2A
and TOP2B homologues have been identified in at least 97 species, including mice, chicken and
zebrafish, and appears to be specific to vertebrates.
3. Protein Characterisation
TOP2A and TOP2B are paralogues that share significant sequence identity; they both have an
N terminal ATPase domain, a central breakage and re-joining domain and a C-terminal domain.
Limited proteolysis revealed the accessible domain boundaries; the domains and the location of the
proteolytic sites are indicated in Figure 1 [9]. The domain arrangement is conserved between all type
II topoisomerases, from bacterial and phage enzymes through to human enzymes. TOP2B shares
68% identity at the amino acid level with TOP2A, but this is not spread evenly through the protein.
The N-terminal three quarters of the enzyme, bearing the ATPase domain and the central breakage
re-joining domain, share 78% amino acid identity while the least conserved domain C-terminal domain
shares only 34% amino acid identity. The divergent sequence of the C-terminal domain suggests it may
play a role in the differential activities of the two isoforms both in vitro and in vivo. The domains are
conserved from bacterial gyrase to human TOP2 [11]. Amino acid comparisons reveal a number of very
conserved motifs, shown in Figure 1, and include RP-YIGS, G-G-P motif, the G-loop consisting of three
conserved glycine’s, EGDSA, PLRGK and IMTDQDQDG motifs, and YKGL and RY where Y is the
active site tyrosine [11]. Production of recombinant protein enabled studies where absolutely conserved
residues were mutated. Mutation of residues E477, R503 and R505 caused loss of function in vivo,
and mutation of E477 and K505 altered the magnesium optima in vitro. Residues D557, D559 and D561
are conserved in type I & II topoisomerases, and comparisons with DNA polymerases suggested that
they are involved in magnesium co-ordination [7]. A number of these conserved residues, E477 and
G478 in EGDSA; G504 in PLRGK; D557, D558 and G562 in IMTDQDQDG are anchor residues in the
TOPRIM domain conserved between type 1A and type II topoisomerases, DnaG-type primases, OLD
family nucleases and RecR proteins [22]. The crystal structure of the TOP2B core including the TOPRIM
domain has been reported [23], and the core of TOP2A has also been crystallised [24]. This domain of
TOP2A and TOP2B displays structural similarity between the two isoforms and with the yeast TOP2
core [25]. The structure and mechanism have been extensively reviewed, see for example [25–27].
The ATPase domain of TOP2A has been crystallised [28], but not that of TOP2B. There is no structural
data on either TOP2A or TOP2B C-terminal domains. The C-terminal domain has least homology
between the isoforms and is the site for the nuclear localisation signals and many post translational
modifications including phosphorylation, sumoylation, ubiquitination, acetylation [29]. Recombinant
proteins have been used to determine in vitro activities, and in vitro both isoforms exhibit strand
passage activity, evidenced by decatenation and relaxation assays. Constructs with the CTDs swapped
between the isoforms were used to investigate the function of the CTD in vitro [30,31]. Truncated
TOP2B lacking the CTD bound to DNA most strongly, suggesting the CTD may have a negative
regulatory role on DNA binding. In cells the CTDs confer isoform specificity [32,33].
4. Expression of TOP2B
The availability of cDNA clones to TOP2B and TOP2A allowed various groups to visualise
the RNA transcripts by northern blotting, and in situ hybridisation. Northern Blotting analysis of
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total RNA extracted from 22 tissues in 3-month-old mice showed that the thymus expressed the
highest levels of both Top2a and Top2b. For Top2a the spleen and bone marrow also showed high level
expression. Testis and intestine expressed an intermediate level of Top2a and ovary, heart, breast and
stomach showed low level expression. Top2a was not detectable in the other tissues studied. Top2b
expression was detectable in 19 of the tissues analysed [34]. Northern blotting of RNA extracted from
tissues of two-week-old rats also showed high levels of Top2a in spleen and thymus, but not in brain,
lung, heart, liver, intestine or muscle. As seen in murine tissues, Top2b was also expressed more widely
in rat tissues [13].
Top2a and Top2b expression was analysed in murine liver and brain before and after birth.
Strikingly Top2b was induced more than 6 fold in the brains of newborn mice compared to embryos,
but not in liver, suggesting an important role in neonatal brain [34]. Developing rat brain has also been
analysed. Northern blotting on RNA extracted from rat brain showed high levels of Top2a in embryonic
rat brain and in the cerebellum 2 days after birth, but Top2a levels were undetectable 4 weeks after birth.
The pattern of expression suggested Top2a is only expressed in proliferating cells. In contrast, Top2b was
present in the embryo and in the post-natal stages sampled (fetal 15 days & 19 days; postnatal 2 days,
2, 4, 12 and 32 weeks). More detailed location of transcripts was determined by in situ hybridisation of
rat brain sections from postnatal day 10. Top2a was only seen in the proliferating regions, whereas the
signal for Top2b was much more widespread and very intense in the cerebellum. This is shown clearly
in an in situ figure in Tsutsui et al., 1991 [13].
RNA in situ in human fetal tissues (kidney, brain, intestine, liver, lung and placenta) showed
differential expression of TOP2A and TOP2B, with TOP2A expressed most strongly in zones of
proliferation [35]. In situ hybridisation of foetal cortex showed TOP2B expressed through the cortex [36].
This study also analysed the protein expression in human foetal brain using immunohistochemistry;
this showed that TOP2A protein was present in regions of cell division and that TOP2B protein was
present in both proliferative and post mitotic areas.
TOP2 protein and activity levels were analysed in rat brain. TOP2A was present during
embryogenesis and up to post-natal day 1, whilst TOP2B was expressed at all ages [37]. TOP2
protein levels in murine tissues have been analysed by western blotting [38], whilst human TOP2
protein levels have been analysed by immunohistochemistry (see for example [39,40]). These studies
showed TOP2A tightly associated with tissues containing proliferating cells whilst TOP2B is expressed
more widely, including in post mitotic tissues. Transcriptome analysis of human tissues via the
GTEx portal (www.gtexportal.org) reveals wide expression of TOP2B with highest expression in the
cerebellum, while microarray analysis of TOP2B expression in primary human cells BioGPS.org) also
demonstrates broad expression and highlights high expression in CD34+ bone marrow cells.
5. TOP2B In Vivo Functions
A type II topoisomerase is essential for mitosis. Both human isoforms can rescue yeast strains
carrying a temperature sensitive mutation in top2 [41,42]. However, in human cells the essential mitotic
functions are carried out by TOP2A [43,44]. Murine embryos lacking Top2a terminated at the 4- or
8-cell stage, confirming that mammalian cells require Top2a [45]. Mice lacking Top2b developed in
utero, but the pups died shortly after birth due to lack of innervation of the diaphragm. Motor axons
failed to contact the skeletal muscle and sensory axons failed to enter the spinal cord [46]. Conditional
inactivation of Top2b in brain tissue using a conditional Cre-loxP system resulted in altered brain
structures and abnormal cerebral lamination. Corticogenesis was adversely affected and neurons
failed to migrate normally [47]. NURR1 (nuclear receptor related 1 protein) regulates expression of
Top2b; in Nurr1 knockout mice Top2b is downregulated [21], suggesting Top2b is a downstream target of
Nurr1. A number of studies have reported that TOP2 inhibitors reduce neurite formation, and isolated
neurones from Top2b null embryos exhibit shorter neurites than controls [48,49]. Furthermore, genes
regulated by TOP2B affect neuronal survival [50]. Since Top2b is regulated by NURR1 and NURR1 is
known to be involved in the regulation of the dopaminergic system in the brain, TOP2B may have
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a role in axon genesis in dopaminergic neurons. A murine model in which Top2b was deleted from
cardiomyocytes using a Cre-loxP showed protection from the cardio toxic effects of doxorubicin,
confirming TOP2B plays a role in doxorubicin cardiotoxicity [51].
In zebrafish top2a is an essential gene [52]. Maternally encoded Top2a enables early development
before the mid-zygotic transition, but transcription of top2a is required after this point, top2b cannot
substitute [53,54]. A zebrafish screen to detect neurite patterning errors identified a top2b mutant
(notorious, noto) with impaired neurite targeting to the inner plexiform layer. This affects axon
guidance to the retina [55], further implicatingtop2b in neural development.
Non-replicating spermatids were shown to contain topoisomerase by Roca and Mezquita in
1989 [4], providing early evidence of a second type II topoisomerase. This study was ahead of its
time, since more recently TOP2B has been demonstrated to have several important functions in sperm
development. For example, TOP2B and PARP co-ordinate the chromatin reorganisation in developing
spermatids when histone proteins are replaced by transition proteins and then by protamines [56–62].
6. TOP2B as an Anti-Cancer Drug Target
TOP2 carries out its strand passage activity by introducing a transient enzyme-bridged
double-strand break in one DNA duplex segment through which a second segment is passed.
Each protomer of the dimeric enzyme remains covalently linked to the 5′-end of the DSB via a
phosphotyrosyl linkage during this process. The enzyme subsequently religates the break and is
released. Human type II DNA topoisomerases are the molecular target for a number of drugs used in
cancer chemotherapy. These drugs, referred to as TOP2 poisons, inhibit the religation step, and thus
stabilise the normally transient enzyme-bridged DNA DSB that occurs during the TOP2 strand-passage
reaction. These TOP2-DNA covalent complexes are cytotoxic and in sufficient quantity result in loss
of cell viability. Clinically relevant TOP2 poisons include doxorubicin, epirubicin, daunorubicin,
idarubicin, mitoxantrone, etoposide and mAMSA. There are extensive numbers of reviews on this
topic, see, for example [63–65]. Interestingly, new combinations including these drugs are still being
tested in clinical trials. For example, a recent trial found that mAMSA could reduce relapse incidence
in AML-patients [66].
The discovery of TOP2B raised the question of whether TOP2A, TOP2B or both isoforms are
targeted by different TOP2 poisons. However, a series of studies demonstrated that both TOP2B and
TOP2A are targeted by TOP2 poisons. For example, in clongenic assays, murine embryo fibroblasts
lacking Top2b were less sensitive to mAMSA than wild type cells and also demonstrated some resistance
to mitoxantrone and etoposide [67]. This was confirmed in human cells lacking TOP2B, where TOP2B
null cells showed the greatest resistance to mAMSA and mitoxantrone, and also showed resistance to
etoposide and doxorubicin. Notably, in this study TOP2B−/− null cells were significantly less sensitive
to mAMSA and mitoxantrone than were TOP2A+/− heterozygotes, while for etoposide the TOP2A,
heterozygotes demonstrated the greatest resistance [68,69]. Further evidence for targeting of TOP2B by
TOP2 poisons was provided using a yeast ts top2 system expressing functional human TOP2B. Human
TOP2B complements the ts yeast top2 at the non-permissive temperature and this allows the selection
of drug resistance mutants in the human enzyme in vivo. Nine mutated proteins were selected from a
randomly mutated pool that conferred drug resistance to acridines, including mAMSA, confirming
TOP2B is a target for acridines [8,70–72].
Using an isoform-specific microscopy based immunoassay (trapped in agarose DNA
immunostaining or TARDIS assay) [73,74] to detect TOP2-DNA covalent complexes, we showed that
etoposide induces complexes with both TOP2 isoforms, as does mAMSA and mitoxantrone [75–77].
The half-lives of the complexes in cells can be determined using the TARDIS assay. Etoposide-stabilised
complexes have half-lives of 30 min for TOP2A and 15 min for TOP2B in human CCRF-CEM cells [76],
whilst in MEFs the etoposide half-life for Top2a is 40 min and for Top2b is 20 min. For mAMSA the
half-life for both Top2a and Top2b is 15 min and mitoxantrone complexes are much longer lived, with a
half-life of 10 h for Top2a and 6 h for Top2b [76]. The TARDIS assay is a microscopy-based method
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that allows the detection and quantification of TOP2-DNA covalent complex levels in individual cells.
An alternative isoform specific assay is the ICE-assay, which involves ultra-centrifugation to separate
the protein–DNA complexes followed by blotting the collected fractions on a slot blot and probing
with isoform specific antibodies. This method also shows complexes with both TOP2 isoforms [68].
While they are effective and widely used anti-cancer agents, TOP2 poisons are also associated with
therapy-related acute leukaemia, in particular acute myeloid leukaemia (t-AML) [78–80]. These t-AML
cases often exhibit one of a set of recurrent chromosome translocations that drive the development
of the leukaemia, most frequently involving the MLL/KMT2A gene at 11q23, t(15,17)(PML-RARA),
t(8,21)(RUNX1-ETO), or inv(16) (CBFB-MYH11) [79,81]. This raises the question of the relative
contribution of TOP2A versus TOP2B in the aetiology of TOP2 poison-induced t-AML. While in
principle either or both TOP2 isoforms could contribute to the induction of leukaemia-causing
translocations via DNA cleavage at multiple loci followed by mis-repair, several lines of evidence
point to TOP2B as the major contributor. For example, TOP2B is required for most etoposide-induced
chromosome breaks at the MLL/KMT2A and RUNX1 loci using DNA FISH in a human cell line
model [82,83], top2b is required for efficient etoposide-induced recombination in a plasmid integration
assay [84] and TOP2B is implicated in androgen-induced chromosome rearrangements in prostate
cancer [85]. In addition, translocation partner genes such as KMT2A and AF9 or RUNX1 and ETO
are closely juxtaposed in a fraction of cells, and this may be influenced by TOP2B [82,83]. This led
to a model for the aetiology of TOP2 poison induced leukaemia where chromosome translocations
are facilitated by co-localization of genes within common transcription factories, combined with
TOP2B-mediated transcription-linked DNA breaks [78,82,83,86]. Furthermore, a proportion of TOP2B
co-localises at conserved genomic locations with CTCF and members of the cohesin complex including
RAD21 [87], presumably to resolve DNA topological problems. ChIP-seq combined with end-seq
analysis demonstrated that this generates fragile sites in the genome that can contribute chromosome
translocation [87–90]. Notably, t-AML patient associated MLL/KMT2A translocation breakpoints are
enriched within a 1 kb region of intron 11 containing at one end a CTCF binding site [82,89].
7. TOP2B Cell Biology–Cell Cycle Expression
In contrast to its essential role in vertebrate development as observed in mice and zebrafish,
in mammalian cell lines, TOP2B is not essential for cell viability [91,92]. There are cell cycle differences
in TOP2A and TOP2B protein levels. In murine NIH-3T3 cells Top2a decreases 5.5 fold when cells
plateau, whilst Top2b levels decrease by only 20% [93]. NIH-3T3 cells were synchronised by serum
starvation to analyse the effect of the cell cycle on Top2 protein levels; this demonstrated that Top2a
was highest in S phase and G2/M and Top2b was present in all phases of the cell cycle [94]. Studies
on five human leukaemia cell lines (K562, Raji, Molt 4, CCRF-CEM and Jurkat) determined that the
two isoforms had differing salt extractabilities, and this was cell line dependent with the optimal level
varying between 1 and 1.9 M sodium chloride. The optimal salt extractability was as efficient as DNase
I/RNase A digestion and SDS solubilisation [95]. TOP2 levels were quantified by western blotting
with a standard curve of purified recombinant TOP2A or TOP2B and expressed as monomers per
cell. Exponentially growing K562 cells contained 440,000 monomers of TOP2B and 570,000 monomers
of TOP2A. Exponentially growing Raji cells were compared to confluent cultures. Exponentially
growing cells contained 720,000 monomers of TOP2A and 1280,000 monomers of TOP2B. In contrast
the confluent cells contained 300,000 monomers of TOP2B but only 60,000 monomers of TOP2A.
In peripheral blood lymphocytes only TOP2B was detectable (290,000 monomers), consistent with
differentiated cells lacking TOP2A, and in ALL patient blasts only TOP2B was detectable [95]. This is
consistent with the majority of blasts being non-proliferating [96,97].
Proliferation dependent topoisomerase II content has been reported to be a determinant of
topoisomerase II mediated drug action, with topoisomerase levels being higher in log phase cells
than in quiescent plateau phase cells from several species. These studies included cell lines derived
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from mice, Chinese hamster and human; cycling cells were more sensitive to drugs targeting DNA
topoisomerase than quiescent plateau phase cells [98–102].
We present new data investigating drug targeting and cytotoxicity on rapidly proliferating K562
cells that have not been perturbed by serum starvation, separated by size using centrifugal elutriation.
The buffer flow rate determines the size of cells eluted from the rotor. Cells are loaded into the
chamber at low flow rate and as the flow rate is increased cells start to elute. Smallest cells (G1
phase cells) are eluted at lower flow rates than larger cells (G2/M phase cells); fractions collected
at the different flow rates had different proportions of each cell cycle phase. As expected, the first
fractions eluted were enriched for G1 cells compared to the starting cell population and contained
fewer G2/M cells; the next fraction (17 mL/min) had more S-phase cells and fewer G2/M cells than
the starting population, and the later fractions were enriched for G2/M cells, with few or no G1 cells.
All the fractions contained S phase cells, but the percentage of S phase varied between 33% and 60%,
with 13 mL/min having the lowest percentage of S phase cells and 20 mL/min having the highest
percentage of S phase cells (Figure 2A).
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Immunofluorescence analysis of each elutriation fraction showing the percentage of each fraction in 
lateS/G2/M determined by CENPF immunofluorescence and the percentage of mitotic cells 
determined by DAPI staining. (C,D) TOP2A and TOP2B protein level per cell was determined by 
quantitative immunofluorescence [77], the data shown represent the mean ± SEM of median values 
obtained from three replicate experiments. Statistical analysis was carried out using one way ANOVA 
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DNA content, which is an indicator of cell cycle position, and also by immunofluorescence using two 
cell cycle markers (CENPF and H3Ser10P). G1 cells express low levels of CENPF and low phospho-
Figure 2. Elutriation of K562 cells separates the cells according to size. (A) FACS analysis (Flowjo) of
each elutriation fraction showing the percentage of G1, S or G2/M phase cells. (B) Immunofluorescence
analysis of each elutriation fraction showing the percentage of each fraction in lateS/G2/M determined
by CENPF immunofluorescence and the percentage of mitotic cells determined by DAPI staining. (C,D)
TOP2A and TOP2B protein level per cell was determined by quantitative immunofluorescence [77],
the data shown represent the mean ± SEM of median values obtained from three replicate experiments.
Statistical analysis was carried out using one way ANOVA (* p < 0.05; *** p < 0.0001).
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The separated cells were then analysed in a range of ways. FACS analysis was used to determine
DNA content, which is an indicator of cell cycle position, and also by immunofluorescence using
two cell cycle markers (CENPF and H3Ser10P). G1 cells express low levels of CENPF and low
phospho-H3Ser10, while late S and G2/M cells contain increasing levels of CENPF, with highest
levels in G2/M cells (Figure 2B), and condensing/condensed mitotic chromosomes are decorated
with phospho-H3Ser10 [103,104]. TOP2A and TOP2B protein levels were determined on a single
cell basis by quantitative immunofluorescence for each fraction. In K562 cells the levels of TOP2A
increased significantly as the proportion of cells in G2/M phase increased in fractions collected at
24, 28 and 31/35 mL/min (Figure 2C) whilst TOP2B did not vary significantly between the fractions
(Figure 2D). This is consistent with previous studies which showed TOP2A levels were highest in cells
in G2/M phase.
To determine if the K562 cell response to TOP2 drug targeting varied with cell cycle phase, we took
the starting mixed culture and fractions collected at 10, 13, 17, 20, 24 mL/min and treated them with
the TOP2 targeting drug etoposide for one hour (it was not possible to test the 28 mL/min & 31/35
mL/min fractions as too few cells were present in these fractions). Using the trapped in agarose DNA
immunostaining (TARDIS) method we were able to detect TOP2A and TOP2B covalent complexes in
all the fractions following exposure to 100 µM etoposide for one hour. For TOP2A, complexes were
also efficiently formed in cells from each fraction following exposure to 10 µM etoposide; for TOP2B
10 µM etoposide resulted in a close to background signal for each fraction. An example of the data
from a single elutriation experiment is shown in Figure 3A,B. Combined data from three independent
elutriations revealed no significant difference in the formation of TOP2A or TOP2B complexes between
the fractions or compared to the starting mixed population. To determine whether cell-cycle position
affected etoposide-induced DSB formation, γH2AX quantitative immunofluorescence was used.
γH2AX signal was seen in all fractions following exposure to 5, 10 or 100 µM etoposide for one hour,
and the signal increased with etoposide concentration. Compared to the starting mixed population,
two-way ANOVA of all three doses and all fractions tested indicted that the 10/13 mL fraction had
lower levels of γH2AX integrated fluorescence. The 10/13 mL fraction contained fewer S phase
cells than the starting population or the other four fractions tested and had the highest level of G1
cells (Figure 3C).
Cytotoxicity assays were carried out on the starting mixed population and on the 10, 13, 17, 20,
24 mL/min fractions. Cells were treated for 1 h with etoposide and then placed in drug-free medium
for 24, 48 or 96 h. Cell counts were analysed by population doubling. Etoposide concentrations of
0.5, 5, 10 or 100 µM were used. Figure 4 shows the population doubling 24, 48 or 96 h after a 1-h
drug exposure. Population doubling was similar in the mixed population and all the fractions tested
following exposure to 0.5 µM etoposide for one hour followed by growth in drug free media. Indeed,
after 0.5 µM for 1 h, there seemed little difference in population doubling compared to the untreated
fractions. Following exposure to 10 or 100 µM for one hour followed by growth in drug free media
for 24 or 48 h, the population doubling was noticeably reduced, in some cases dropping below 0,
indicating cytotoxicity and loss of cells. Compared to the starting mixed population the G1/early
S-enriched 17 mL/min fraction was most affected. After 96 h in culture, there appeared little difference
apart from fraction 17 that had been exposed to 100 µM etoposide.
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treated with etoposide (10 or 100 µM) and TOP2-DNA covalent complexes were detected and
quantified by TARDIS analysis [73–75,77]. The data are shown as scattergrams, derived from a single
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elutriated fraction were treated with etoposide (5, 10 or 100 µM) or solvent (DMSO) and analysed
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quantitative immunofluorescence [77]. The data are shown as means of the medians obtained from
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In summary, for non-perturbed proliferating K562 cells separated into fractions based on size and
cell cycle phase prior to exposure to etoposide for one hour, no differences in the level of topoisomerase
II covalent complexes were seen in the different fractions (Figure 2A,B). Fluorescence intensity for
gamma H2AX signal only differed in the 10/13 mL/min fractions which contained the most G1 phase
cells (Figure 2C). In these fractions the gamma H2AX signal was lower, suggesting fewer double strand
breaks were formed when there were fewer S phase cells. Minimal difference in cytotoxicity was seen
with 0.5 µM etoposide when comparing the fractions with the starting population, but with higher
concentrations the most sensitive fraction was that collected at 17 mL/min, containing early S phase
cells. This indicates that early S phase cells are more sensitive to etoposide, consistent with observations
in previous studies in cells synchronised with serum starvation [98–102]. However, since the levels
of TOP2-covalent complexes were similar in all fractions tested (Figure 2A,B), events downstream of
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complex formation, such as replication fork collision, may be responsible for the increased sensitivity
to etoposide in early S phase cells, reviewed in Yan et al., 2016 [105].
8. Subcellular Location of TOP2B Protein
TOP2 is predominantly nuclear; the C-terminal domain of TOP2A and TOP2B contain nuclear
localisation signals [106,107] and both isoforms have nuclear export signals [108,109]. The interphase
subcellular location of TOP2B has been the topic of a number of studies. Zini et al. reported that
TOP2B was nucleolar [110], whilst another group found Top2b in both the nucleoplasm and nucleolus,
and frequently associated with heterochromatin [111] and a third study suggested TOP2B was excluded
from the nucleolus [112]. Chaly and Brown analysed the subcellular location of TOP2A and TOP2B
under different fixation conditions with a number of antibodies. The conclusion of this study was
that TOP2B was present largely in the nucleoplasm with some distribution in the nucleoli which was
variable depending on antibody and fixation condition [113]. Studies with antisera raised to TOP2B
CTD and using TOP2B CTD galactosidase tagged constructs in HeLa and monkey COS7 cells showed
nucleoplasmic staining with no evidence for significant nucleolar enrichment [114]. Onoda et al.,
2014 [115] show shuttling of TOP2B between the nucleolus and the nucleoplasm, and suggest that the
enzyme is active when in the nucleoplasm. Cowell et al., 2011 demonstrated that Top2b is enriched
in heterochromatic regions in mouse epithelial cells and relocates to give a pan nuclear staining
upon treatment with the histone deacetylase inhibitor TSA [116], treatment which also causes loss
of HP1 from heterochromatin [117]. Christensen et al., 2002, using photo bleaching, demonstrated
that TOP2A and TOP2B were mobile within the nucleus [118]. Cell lysis conditions can affect the
distribution of TOP2 in immunofluorescence localisation studies, and hypotonic cell lysis produced an
axial pattern. During mitosis most TOP2B dissociates from chromatin, whilst most TOP2A remains
chromosome bound [112,119] and the mitotic functions of TOP2A cannot be carried out by TOP2B [43].
However, some studies also find TOP2B is associated with mitotic chromosomes [120,121]. In addition,
two studies have indicated the presence of Top2b in mitochondria using mass spectroscopy, the first in
2003 [122] and the most recent in 2014 [123] where Top2a was also detected in mitochondria.
9. Protein–Protein Interactions
A wide range of approaches have been used to identify protein interaction partners of TOP2B.
One of the first proteins identified as an interacting protein was CD3 epsilon; the cytoplasmic region of
CD3 epsilon was used as bait to screen an expression library and it bound to the C-terminal domain of
TOP2B [124]. The TOP2B interacting protein, DNA topoisomerase IIB binding protein one (TOPBP1)
was identified in a yeast two hybrid screen with the C-terminal part of TOP2B (1143–1621) as bait [125].
UBC9, a SUMO1 conjugating enzyme, was identified as a TOP2B interacting partner via a 2 hybrid
screen [126]. Phosphorylation of TOP2B by a range of kinases has been reported including CKII,
PKC, PLK, Aurora B, cyclin B/cdc2 and MAPK [127–131]. Direct interaction with TOP2B has been
reported for a number of kinases. TOP2B was pulled out when ERK1 was used as bait in a protein
expression screen, clone S64 encoded residues 1398–1592 of TOP2B [132]. Using a combination of
site directed mutagenesis and mass spectroscopy, three sites that could be phosphorylated in vitro by
ERK1 were identified between residues 1398 and 1592: Serine 1419, Serine 1445 and Serine 1471 [133].
Other interacting kinases include Protein Kinase Cζ [134] and Casein Kinase IIβ [135]. TOP2B has
been shown to interact with tumour suppressor proteins p53 [136,137] and pRB [138,139]. To map
the pRB interaction a yeast two hybrid system was used. This showed that the C-terminal domain
of TOP2B interacted with the A box of pRB, and GST fusion protein pulldowns indicated the last
116 amino acid residues of TOP2B were sufficient for this interaction [139]. Histone deacetylates
HDAC1 & HDAC2 have also been shown to interact directly with TOP2B [140]. TOP2B has also
been reported to be present within several complexes involved in ligand mediated transcriptional
regulation, these include an RARB/TOP2B repressor complex [141], the Groucho/TLE1 repressor
complex containing PARP and TOP2B [142] and a complex containing TOP2B, PARP, DNA-PK and
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KU antigen [143]. Wong et al., 2009 also found TOP2B to be a component of a transcriptional complex
containing DNA-PK and KU antigen that is recruited to the fatty acid synthase (FAS) gene in response
to insulin [144]. An interaction between KU and TOP2B was also reported by Matheos et al., 2002 [145].
Via programmes such as STRING (https://string-db.org/) [146] it is possible to view a range of
interactions as they are reported.
Most recently, biotin ID mapping has been used to identify proteins interacting with TOP2B.
A biotin ligase TOP2B fusion protein was expressed in HeLa cells and proteins in close proximity
to TOP2B become biotinylated. They were then isolated on streptavidin beads and identified by
mass spectrometry. This study reported 25 high confidence interacting partners for TOP2B (TOP2A,
TOP1, CTCF, SMC1A, PDS5B, STAG1, STAG2, PDS5A, NIPBL, RAD21, HMGA1, YY1, ZNF451,
ZNF512, ZNF362, DDX18, DDX31, PHF2, SDAD1, CBX8, LRIF1, HDGF, SRBD1, RRP15, MORC2) [87].
Interestingly recent mass spec analysis of the calf thymus protein purified in 1987 [147] confirmed
the TOP2 purified from calf thymus contained both TOP2A and TOP2B and it co-purified with three
proteins reported to interact with TOP2B via biotin ID mapping (TOP1, DDX18, SMC1A) [87] and with
proteins reported to functionally interact with TOP2B such as PARP1.
10. Transcriptional Roles of TOP2B
DNA topoisomerases are required to relieve the topological stress during transcription, as detailed
in the twin domain supercoiling model [148]. Both type II isoforms TOP2A and TOP2B have been
reported to be involved in transcriptional regulation; Top2a appears to be required for gene regulation
and priming in embryonic stem cells whilst a switch to Top2b occurs during differentiation [50,149].
TOP2B has been reported to mediate ligand-mediated transcription via a mechanism that introduces
a double strand break [85,141,143,150–152]. A number of groups have reported TOP2B ChIP-seq
studies, the first reported by Sano et al. in 2008, using rat cells [153]. More recent studies have
reported ChIP-seq from human MCF7 cells [154], primary mouse B cells [89], mouse liver [87] and
mouse brain [155,156]. Chip-seq analyses in humans [154] and mouse [87] identify transcription factor
binding sites within the peak sequences associated with topoisomerase IIB; these included CTCF, SP1,
EGR1, PAX5, and TFAP2. Furthermore, as described above, Uusküla-Reimand et al. [87] also showed
that TOP2B is associated with CTCF and members of the cohesin complex at domain boundaries.
In addition, Canela et al. [89] demonstrated that loop anchor regions bound by cohesin and CTCF are
sensitive to etoposide-induced DSBs identified by end-seq; these breaks are co-incident with TOP2
ChIP peaks suggesting they are mediated by TOP2, probably TOP2B. This is consistent with a role for
topoisomerases and transcription in mediating domains of supercoiling flanked by GC-AT boundaries
and CTCF insulator protein-binding sites [157]. Topoisomerases have been reported to be particularly
important for the transcription of long genes [158–160].
11. Conclusions
The first report of topoisomerase IIβ protein was in 1987; that it was encoded by a separate gene
was subsequently confirmed by cloning of the cDNA and mapping the gene location. Research in
the first 10 years after TOP2B was reviewed in Austin and Marsh 1998 [29]. Subsequent research
elucidated the biochemistry of this protein via site directed mutagenesis and crystallography of the
enzyme core breakage reunion domain. Protein–protein interactions reveal that TOP2B interacts
with various kinases responsible for phosphorylation; the cellular function of post translational
modifications of TOP2B is an open question. TOP2B is associated with TOP2A in biotin ID mapping
studies, raising the question of the presence and role of TOP2A/B heterodimers in cells. The murine
knockout reported in 2000 demonstrated its importance for neural development. Studies more recently
have demonstrated the importance of TOP2B in transcriptional regulation and genome organisation.
Nevertheless, the detailed molecular mechanism of transcriptional regulation by TOP2B remains to be
elucidated. A murine knockout in cardiomyocytes implicated TOP2B in cardiotoxicity [51]. TOP2B has
also been implicated in the development of therapy related leukaemia [78,82,83]. The observations
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have led to the suggestion that drugs selectively targeting TOP2A may have clinical advantages;
further work will be needed to determine if this is correct.
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Abbreviations
CTCF CCCTC-binding factor
CTD C terminal domain
DSB Double strand DNA break
t-AML Therapy-related acute myeloid leukaemia
TARDIS Trapped in agarose DNA immunostaining
TOP2A DNA topoisomerase IIα
TOP2B DNA topoisomerase IIβ
TOP2 DNA topoisomerase II
ts Temperature sensitive
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